Clinical trials: Immunoglobulin A Nephropathy, open to volunteers
IgAN, Immunoglobulin A Nephropathy (IgAN)
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.
- Conditions
- IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
- Trial name
- HS-10542 (NCT07474636)
- Testing
- HS-10542 High Dose, HS-10542 Low Dose
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Immunoglobulin A Nephropathy (IgAN)
A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with IgAN.
- Trial name
- NCT07135219
- Testing
- Biological: cizutamig
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University First Hospital
Immunoglobulin A Nephropathy
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
- Trial name
- NCT06952426
- Testing
- No intervention, Other treatment, Iptacopan
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Glomerulonephritis, Immunoglobulin A Nephropathy
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Idiopathic immunoglobulin A nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis in the world. Approximately 40% of IgAN patients reach end-stage kidney disease (ESKD) 20 years after their kidney biopsy.
- Trial name
- CLIgAN (NCT04662723)
- Testing
- Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor
- Where
- 2 sites in Italy
- Volunteers
- 878 people
- Sponsor
- Fondazione Schena
Immunoglobulin a Nephropathy
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.
- Trial name
- NCT06635772
- Testing
- HS-10390, Irbesartan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hansoh BioMedical R&D Company
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association